Pre-made Apamistamab biosimilar ( Whole mAb Radiolabelled, anti-PTPRC therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-029
Anti-PTPRC therapeutic antibody (Pre-made Apamistamab biosimilar,Whole mAb Radiolabelled) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. ... It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PTPRC therapeutic antibody (Pre-made Apamistamab biosimilar,Whole mAb Radiolabelled)|
|Format||Whole mAb Radiolabelled|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center|
|Conditions Active||Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma|
|Conditions Discontinued||Hodgkin's disease;Non-Hodgkin's lymphoma|